Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

New warning on hepatitis C drugs

Roger Collier
CMAJ January 23, 2017 189 (3) E120-E121; DOI: https://doi.org/10.1503/cmaj.109-5369
Roger Collier
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Health care providers should screen patients for hepatitis B infections (including past infections) before starting them on direct-acting antivirals for hepatitis C, warned Health Canada. The drugs have been found to reactivate hepatitis B, though the risk appears to be low. Still, both patients and heath care providers should be aware of the potential problem, noted Health Canada.

“As a result, Health Canada is working with manufacturers to strengthen the prescribing information for these drugs with a new warning about this risk,” Health Canada said on its website. The brand names of the direct-acting antivirals available in Canada are: Daklinza, Epclusa, Galexos, Harvoni, Holkira Pak, Sovaldi, Sunvepra, Technivie and Zepatier.

In a safety review of the drugs, Health Canada found no Canadian cases of hepatitis B reactivation, but did find 13 cases internationally. Complications of hepatitis B infection include liver failure and death. If patients are already receiving direct-acting antivirals for hepatitis C, they should be monitored by their health care providers during and after treatment, recommended Health Canada.

“While Health Canada’s notice may be prudent, I am not sure it is necessary given how infrequently hepatitis B reactivation occurs in these instances. It is important, however, for all patients who have hepatitis C to be tested for hepatitis B, particularly since the routes of transmission are similar,” Dr. Morris Sherman, chairman of the Canadian Liver Foundation, said in a statement. “In terms of frequency, this is at best a rare event, but for the patient this can have potentially serious outcomes, such as acute hepatitis with liver failure, or progression to cirrhosis and liver cancer over the longer time frame.”

The Health Canada warning and recommendations echo those of health regulators in other countries. The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (EMA) also released a warning last week, its second of the year.

“This is thought to be the consequence of the rapid treatment-induced reduction in hepatitis C virus, which is known to suppress the hepatitis B virus, and the lack of activity against hepatitis B virus of direct-acting antivirals,” the EMA said in a press release.

The United States Food and Drug Administration (FDA) issued a safety announcement in October. The agency identified 24 cases of hepatitis B reactivation between Nov. 22, 2013 and July 18, 2016. In a few cases, noted the FDA, the reactivations resulted in serious liver problems or death.

Figure

Direct-activing antivirals for hepatitis C can reactivate hepatitis B.

Image courtesy of jarun011/iStock

“As a result, we are requiring a Boxed Warning, our most prominent warning, about the risk of HBV [hepatitis B virus] reactivation to be added to the drug labels of these DAAs [direct-acting antivirals] directing health care professionals to screen and monitor for HBV in all patients receiving DAA treatment,” stated the FDA.

“Serious life-threatening HBV reactivation is very rare, but the stakes are very high. Therefore this problem should be taken seriously,” Dr. Charles Landis of the University of Washington’s medical department, said in an email.

“I do think increased monitoring is enough to address the problem,” added Landis, who cowrote a 2015 case report of hepatitis B reactivation for the Journal of Medical Case Reports.

The reactivation of hepatitis B by directing-acting antivirals, which are highly effective in treating hepatitis C, will pose a bigger problem in countries struggling to control both hepatitis C and B, such as China.

“With a CHC [chronic hepatitis C] population estimated to be 30 million, 3 to 12 million CHC Chinese will be at risk of HBV,” Dr. George Lau, chairman of the Humanity and Health Medical Group in Hong Kong, said in an email.

Lau was a coauthor on a recent observational study on hepatitis B reactivation among patients receiving direct-acting antivirals in Clinical Gastroenterology and Hepatology. The researchers followed 327 patients taking direct-acting antiviral agents for hepatitis C in areas of China where hepatitis B is endemic. Patients were tested for hepatitis B every two weeks during treatment and once a month for 12 weeks after treatment. Ten patients tested positive for hepatitis B, though only three cases were attributed to DAA-related reactivation.

“The US FDA warning based on our study and others is of paramount importance as DAAs will soon be made available in China,” said Lau. “Left unnoticed, as reported in our study, a lot of our Chinese patients will suffer unnecessarily.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (3)
CMAJ
Vol. 189, Issue 3
23 Jan 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
New warning on hepatitis C drugs
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
New warning on hepatitis C drugs
Roger Collier
CMAJ Jan 2017, 189 (3) E120-E121; DOI: 10.1503/cmaj.109-5369

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
New warning on hepatitis C drugs
Roger Collier
CMAJ Jan 2017, 189 (3) E120-E121; DOI: 10.1503/cmaj.109-5369
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Providing abortions to Americans could land Canadian doctors in legal trouble — without CMPA assistance
  • Troubling rise in suicides linked with common food preservative
  • Weak SARS-CoV-2 vaccine booster campaign resurrects specter of health care hesistancy
Show more News

Similar Articles

Collections

  • Topics
    • Drugs: adverse reactions
    • Infectious diseases

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire